MCID: PRL017
MIFTS: 47

Prolymphocytic Leukemia malady

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Prolymphocytic Leukemia

Aliases & Descriptions for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 14 69
Leukemia, Prolymphocytic 42
Leukemia Prolymphocytic 52

Classifications:



External Ids:

Disease Ontology 12 DOID:1039
MeSH 42 D015463
NCIt 47 C3181
UMLS 69 C0023486

Summaries for Prolymphocytic Leukemia

MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to t-cell prolymphocytic leukemia and b cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Development IGF-1 receptor signaling. The drugs Cefepime and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Wikipedia : 71 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Related Diseases for Prolymphocytic Leukemia

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 76)
id Related Disease Score Top Affiliating Genes
1 t-cell prolymphocytic leukemia 12.4
2 b cell prolymphocytic leukemia 12.4
3 splenic manifestation of prolymphocytic leukemia 11.9
4 leukemia 10.9
5 chronic lymphocytic leukemia 10.4
6 lymphoma 10.2
7 lymphomatoid granulomatosis 10.1 CD5 ZAP70
8 retinal dystrophy with inner retinal dysfunction and ganglion cell abnormalities 10.1 CD38 ZAP70
9 chromosome 11q duplication 10.1 CD38 ZAP70
10 extragonadal seminoma 10.1 CD5 MYC
11 parotitis 10.1 CCND1 CD5
12 villoglandular endometrial endometrioid adenocarcinoma 10.1 ATM CCND1
13 uterine ligament endometrioid adenocarcinoma 10.1 CCND1 CD5
14 hemorrhagic proctocolitis 10.1 CCND1 MYC
15 hairy cell leukemia 10.1
16 macrostomia-preauricular tags-external ophthalmoplegia syndrome 10.0 ATM MTCP1 MYC TCL1A
17 arteriosclerosis 10.0 CD38 CD5
18 t-cell leukemia 10.0
19 ectodermal dysplasia 10.0 CCND1 CD5 MYC
20 transient retinal arterial occlusion 9.9 ADA CD38
21 duodenal ulcer 9.9 ATM CD38 CD5 MYC
22 anterior foramen magnum meningioma 9.9 ADA CD38 MYC
23 mantle cell lymphoma 9.9
24 hematopoietic stem cell transplantation 9.9
25 large granular lymphocyte leukemia 9.9
26 marantic endocarditis 9.9 ATM CCND1 MYC TCL1A
27 melanoma metastasis 9.9 ATM CCND1 CD5 MYC
28 hemoglobinopathy 9.9 ADA CCND1 CD5
29 bladder disease 9.9 CCND1 CD5 MYC TCL1A
30 cutis laxa, autosomal recessive, type ib 9.8 CCND1 CD38 MYC
31 ectopic thymus 9.8 ADA ZAP70
32 t-cell large granular lymphocyte leukemia 9.8
33 kaposi sarcoma 9.8
34 sarcoma 9.8
35 ataxia-telangiectasia 9.8
36 b-cell lymphomas 9.8
37 meningitis 9.8
38 diffuse large b-cell lymphoma 9.8
39 ataxia 9.8
40 theileriasis 9.8 CCND1 CD38 CD5 MYC
41 hyperaldosteronism, familial, type ii 9.8 CD38 CD5 FCER2 ZAP70
42 childhood brain stem glioma 9.7 ATM CCND1 CD38 CD5 ZAP70
43 purpura 9.7
44 endotheliitis 9.7
45 myocardial infarction 9.7
46 thrombocytopenia 9.7
47 retinitis 9.7
48 prostate cancer 9.7
49 exanthem 9.7
50 polyradiculoneuropathy 9.7

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia

Symptoms & Phenotypes for Prolymphocytic Leukemia

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.81 CD38 CD5 FCER2 MYC ZAP70 ABCB4
2 endocrine/exocrine gland MP:0005379 9.8 ABCB4 ADA ATM CCND1 CD38 MYC
3 immune system MP:0005387 9.61 ABCB4 ADA ATM CCND1 CD38 CD5
4 reproductive system MP:0005389 9.1 ABCB4 ADA ATM CCND1 MYC TCL1A

Drugs & Therapeutics for Prolymphocytic Leukemia

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 279)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
6
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
7
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
8
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
9
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
10
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
11
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
12
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
13
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
14
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
15
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Ondansetron Approved Phase 3 99614-02-5 4595
18
Dalteparin Approved Phase 3 9041-08-1
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
21
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
23
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
24
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
25
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
26
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
27
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
28
Thiotepa Approved Phase 2, Phase 3,Phase 1 52-24-4 5453
29
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
30
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
31 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Cephalosporins Phase 3,Phase 1
34 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
35 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
36 Renal Agents Phase 3,Phase 1,Phase 2
37 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
38 Analgesics Phase 3,Phase 2
39 Anesthetics Phase 3
40 Anesthetics, Dissociative Phase 3
41 Anesthetics, General Phase 3
42 Anesthetics, Intravenous Phase 3
43 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
44 Excitatory Amino Acid Antagonists Phase 3
45 Excitatory Amino Acids Phase 3
46 Neurotransmitter Agents Phase 3
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
49 Dermatologic Agents Phase 3,Phase 2,Phase 1
50 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 190)
id Name Status NCT ID Phase
1 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3
4 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
5 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
6 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
7 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
8 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
9 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
10 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
11 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
13 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
15 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Active, not recruiting NCT01231412 Phase 3
16 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
17 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2
18 Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Completed NCT00278213 Phase 2
19 Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL) Completed NCT00464633 Phase 2
20 Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias Completed NCT00472849 Phase 1, Phase 2
21 Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Completed NCT00452374 Phase 1, Phase 2
22 Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma Completed NCT00006252 Phase 2
23 Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) Completed NCT01419691 Phase 2
24 Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL Completed NCT01217749 Phase 1, Phase 2
25 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL Completed NCT00546793 Phase 1, Phase 2
26 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
27 Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant Completed NCT01930162 Phase 1, Phase 2
28 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2
29 Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00026351 Phase 2
30 Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma Completed NCT00278161 Phase 2
31 Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Completed NCT00053196 Phase 2
32 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) Completed NCT00005626 Phase 2
33 Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Completed NCT00001637 Phase 2
34 Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer Completed NCT00782379 Phase 2
35 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2
36 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases Completed NCT00453206 Phase 2
37 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
38 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2
39 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
40 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
41 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2
42 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
43 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
44 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon Completed NCT00010283 Phase 1, Phase 2
45 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant Completed NCT01244906 Phase 2
46 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
47 Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL Recruiting NCT02005289 Phase 2
48 PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Recruiting NCT02390752 Phase 1, Phase 2
49 Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant Recruiting NCT02662296 Phase 2
50 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Genetic Tests for Prolymphocytic Leukemia

Anatomical Context for Prolymphocytic Leukemia

MalaCards organs/tissues related to Prolymphocytic Leukemia:

39
T Cells, B Cells, Bone, Bone Marrow, Skin, Heart, Spleen

Publications for Prolymphocytic Leukemia

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 316)
id Title Authors Year
1
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
2
Risk of second cancers in survivors of prolymphocytic leukemia: a SEER data analysis. ( 27924652 )
2017
3
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
4
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
5
GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses. ( 27941777 )
2016
6
PEITC in End-Stage B-Cell Prolymphocytic Leukemia: Case Report of Possible Sensitization to Salvage R-CHOP. ( 27168399 )
2016
7
Brentuximab Vedotin Therapy for Cutaneous Lesions in T-Prolymphocytic Leukemia: A Case Report. ( 27757215 )
2016
8
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
9
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
10
Auer Rod-Like Inclusions in Prolymphocytic Leukemia. ( 26299084 )
2015
11
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
12
Management of prolymphocytic leukemia. ( 26637744 )
2015
13
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
14
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
15
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
16
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
17
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
18
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
19
T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine. ( 26853400 )
2015
20
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
21
Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: AA Single-Center Experience. ( 26422251 )
2015
22
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
23
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
24
A I^/I' T-cell Receptor Prolymphocytic Leukemia and CD4-/CD8- Double-negative Immunophenotype in a Pediatric Patient. ( 25757027 )
2015
25
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
26
Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. ( 24977988 )
2014
27
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. ( 25593528 )
2014
28
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. ( 24446122 )
2014
29
An unusual cause of delirium and debility: refractory hypercalcemia in a man with B-cell prolymphocytic leukemia. ( 25333559 )
2014
30
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement. ( 25310835 )
2014
31
Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. ( 25068103 )
2014
32
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. ( 24825865 )
2014
33
Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC). ( 25130897 )
2014
34
Functional analysis of the SEPT9-ABL1 chimeric fusion gene derived from T-prolymphocytic leukemia. ( 25217890 )
2014
35
B-cell prolymphocytic leukemia carrying t(8;14)(q24;q32), associated with both autoimmune hemolytic anemia and pure red cell aplasia. ( 25501113 )
2014
36
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014
37
B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. ( 24891323 )
2014
38
The MEC1 and MEC2 lines represent two CLL subclones in different stages of progression towards prolymphocytic leukemia. ( 25162594 )
2014
39
Aberrations of MYC are a common event in B-cell prolymphocytic leukemia. ( 25125625 )
2014
40
T-cell prolymphocytic leukemia in a 63-year-old female with a pre-existing T-cell large granular lymphocytic leukemia: Metachronous T-cell leukemias with discordant subset restrictions (CD4 versus CD8) and distinct clonal identities. ( 25238936 )
2014
41
Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. ( 24764733 )
2014
42
Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission. ( 24470149 )
2014
43
Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy. ( 25258193 )
2014
44
Immunophenotypic characterization of T-cell prolymphocytic leukemia. ( 24124154 )
2013
45
[Splenic rupture associated with aggressive conversion of indolent T-cell prolymphocytic leukemia]. ( 23676644 )
2013
46
T-cell prolymphocytic leukemia (T-PLL) with overlapping cytomorphological features with T-CLL and T-ALL: a case initially diagnosed by fine-needle aspiration cytology and immunocytochemistry. ( 21987484 )
2013
47
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. ( 24048415 )
2013
48
Coronary vasculitis associated with T-cell prolymphocytic leukemia. ( 23731632 )
2013
49
Smudge cells following treatment with pentostatin in a patient with B-cell prolymphocytic leukemia. ( 24049774 )
2013
50
Cutaneous presentation of T-cell prolymphocytic leukemia. ( 23513557 )
2013

Variations for Prolymphocytic Leukemia

Expression for Prolymphocytic Leukemia

Search GEO for disease gene expression data for Prolymphocytic Leukemia.

Pathways for Prolymphocytic Leukemia

Pathways related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1 12.24 CCND1 MTCP1 MYC TCL1A
2
Show member pathways
12.16 CCND1 FCER2 MYC
3
Show member pathways
12.13 ATM CCND1 MYC
4 12.12 ATM CCND1 MYC
5 12.03 CD38 FCER2 MYC
6 11.84 ATM CCND1 MYC
7 11.69 ATM CCND1 MYC
8 11.67 CCND1 FCER2 MYC
9 11.53 CD38 CD5 FCER2
10 11.39 ADA CCND1 MYC
11 11.25 ATM CCND1 MYC
12 11.14 CCND1 MYC
13 11.14 ADA ZAP70
14 11.1 CCND1 MYC
15 11.06 CD38 CD5 FCER2
16 11.04 ATM CCND1
17 10.99 CCND1 MYC
18 10.93 CCND1 MYC
19
Show member pathways
10.84 ATM MYC
20 10.83 ATM CCND1 MYC
21 10.44 ATM CCND1 MYC

GO Terms for Prolymphocytic Leukemia

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 placenta development GO:0001890 9.52 ABCB4 ADA
2 positive regulation of cell cycle GO:0045787 9.51 CCND1 MYC
3 positive regulation of B cell proliferation GO:0030890 9.49 ADA CD38
4 liver regeneration GO:0097421 9.48 CCND1 MYC
5 response to morphine GO:0043278 9.46 ABCB4 ADA
6 response to hypoxia GO:0001666 9.46 ABCB4 ADA ATM CD38
7 positive regulation of T cell differentiation GO:0045582 9.43 ADA ZAP70
8 positive regulation of calcium-mediated signaling GO:0050850 9.4 ADA ZAP70
9 response to vitamin E GO:0033197 9.37 ADA CCND1
10 response to drug GO:0042493 9.35 ABCB4 ADA CCND1 CD38 MYC
11 positive regulation of alpha-beta T cell differentiation GO:0046638 9.32 ADA ZAP70
12 re-entry into mitotic cell cycle GO:0000320 9.26 CCND1 MYC
13 response to estradiol GO:0032355 8.92 ABCB4 CCND1 CD38 MYC

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex binding GO:0032403 8.8 ATM CCND1 MYC

Sources for Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....